SETD2: an epigenetic modifier with tumor suppressor functionality
about
High-density array-CGH with targeted NGS unmask multiple noncontiguous minute deletions on chromosome 3p21 in mesotheliomaDistinct molecular profile of diffuse cerebellar gliomas.SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis.Shaping the cellular landscape with Set2/SETD2 methylation.Chronic lymphocytic leukaemia genomics and the precision medicine era.Set2 Methyltransferase Facilitates DNA Replication and Promotes Genotoxic Stress Responses through MBF-Dependent Transcription.Epigenetic therapy with inhibitors of histone methylation suppresses DNA damage signaling and increases glioma cell radiosensitivityTranscription-dependent association of HDAC2 with active chromatin.Genomic landscape of pancreatic neuroendocrine tumours: The International Cancer Genome Consortium.Fine-tuning type I IFN signaling: A new chapter in the IFN saga.Bombyx mori histone methyltransferase BmAsh2 is essential for silkworm piRNA-mediated sex determination.Systematic In Vivo Inactivation of Chromatin-Regulating Enzymes Identifies Setd2 as a Potent Tumor Suppressor in Lung Adenocarcinoma.MLL-fusion-driven leukemia requires SETD2 to safeguard genomic integrity.SETD2-dependent H3K36me3 plays a critical role in epigenetic regulation of the HPV31 life cycleUbiquitin Regulation: The Histone Modifying Enzyme's StorySETD2 mutations in primary central nervous system tumors
P2860
Q28395181-73E00958-0DA7-41EC-8BF7-3330AE55316AQ38602693-6E431C37-A18F-41B3-9ACA-9EB123B5AA52Q38698612-07EE4829-76AE-4C8D-9F55-8024EBE12683Q39225775-8FC7EDD4-42C3-4BAD-A992-C568963882E1Q39263974-C2491677-D839-485C-8773-BEF6A7EB755BQ41664340-6D706136-0CE8-48D7-B5A8-D072E6A3FA0AQ42285151-7A2FD208-0D5B-4CAE-B9D3-32E2CF2143EFQ48186996-C1E72DAC-2709-42AE-B32B-4206110C75D4Q48520101-DE2015EC-FCBD-4D88-B84C-DC8C115B4E8EQ50026084-F4FD5A97-E7BD-41A0-8270-54F3634F2235Q50422178-F145BCDB-DE65-4357-8E2F-1E1F655A05FBQ50891398-9A5B2EB3-0D4E-4CC1-B060-A109F3F1AF6DQ55279675-B7128C16-2137-4A8E-AA52-2F30D60E9E74Q57472357-5A129F94-D998-4430-B226-1DB46C22EFFCQ58700177-0FEB3B76-E3E5-4D04-B777-001B869ADF71Q59136863-E9B1A730-AE5C-438F-9B0A-0A90F6186F3F
P2860
SETD2: an epigenetic modifier with tumor suppressor functionality
description
2016 nî lūn-bûn
@nan
2016 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
SETD2: an epigenetic modifier with tumor suppressor functionality
@ast
SETD2: an epigenetic modifier with tumor suppressor functionality
@en
SETD2: an epigenetic modifier with tumor suppressor functionality
@nl
type
label
SETD2: an epigenetic modifier with tumor suppressor functionality
@ast
SETD2: an epigenetic modifier with tumor suppressor functionality
@en
SETD2: an epigenetic modifier with tumor suppressor functionality
@nl
prefLabel
SETD2: an epigenetic modifier with tumor suppressor functionality
@ast
SETD2: an epigenetic modifier with tumor suppressor functionality
@en
SETD2: an epigenetic modifier with tumor suppressor functionality
@nl
P2093
P2860
P50
P921
P3181
P356
P1433
P1476
SETD2: an epigenetic modifier with tumor suppressor functionality
@en
P2093
Helga Westers
Rolf Sijmons
P2860
P304
50719-50734
P3181
P356
10.18632/ONCOTARGET.9368
P407
P5008
P577
2016-08-01T00:00:00Z